Abstract
BACKGROUND: The benefit of regional nodal irradiation (RNI) following modern primary systemic therapy (PST) in HER2-positive breast cancer (HER2 + BC) remains under investigation. The current study evaluates RNI practice patterns and outcomes based on the pathological response to PST in clinically node-positive (cN+) HER2 + BC.
METHODS: TRYPHAENA and NeoSphere are two randomized phase II trials that investigated PST for HER2 + BC. The current study is a pooled analysis of both trials, focusing on cN + patients treated with HER2-targeted PST followed by breast-conserving surgery. The primary goal is to describe patterns of RNI practicein this population and its impact on breast cancer recurrence-free survival (BCRFS) and loco-regional recurrence-free survival (LRRFS).
RESULTS: Our analysis included a total of 90 patients with cN + disease. Complete nodal pathological response was achieved in 53 patients (58.9%). Patients with ypN0 had a 5-year LRRFS of 95.83% whereas patients with ypN + had 5-year LRRFS of 87.43% (p = 0.105). RNI was used in 16 ypN0 (48.5%) patients and 17 ypN+ (51.5%) patients. Patients treated with RNI had 5-year LRRFS of 93.4% as compared to 92.5% in the no RNI group (p = 0.868). Distant metastasis was detected in 5 patients (5%) with the most common sites being: liver, lung, bone, and CNS. Locoregional recurrence was significantly associated with distant failure (p = 0.002).
CONCLUSIONS: cN + HER2 + BC patients who achieve ypN0 after PST have excellent locoregional control. In contrast, patients with ypN + tend to have lower locoregional control. The utility of RNI in HER2 + BC warrants further investigation.
| Original language | English |
|---|---|
| Pages (from-to) | 996 |
| Journal | BMC Cancer |
| Volume | 25 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jun 4 2025 |
| Externally published | Yes |
Keywords
- Adult
- Aged
- Female
- Humans
- Middle Aged
- Breast Neoplasms/pathology
- Combined Modality Therapy
- Disease-Free Survival
- Lymphatic Metastasis
- Mastectomy, Segmental
- Neoplasm Recurrence, Local
- Erb-b2 Receptor Tyrosine Kinases/metabolism
- Treatment Outcome
- Clinical Trials, Phase II as Topic
- Randomized Controlled Trials as Topic
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS